FDA will argue against rivaroxaban approval for AF indication - TheHeart.Org |
![]() |
TheHeart.Org The drug is available in two doses, 150 mg twice daily and, for a small subset with severe renal impairment, 75 mg twice daily. When the ROCKET-AF study was presented last year at the American Heart Association meeting, reported by heartwire at that |